^
Association details:
| Biomarker: | ALK1 rearrangement |
|---|---|
| Cancer: | Sarcoma |
| Drug: | Lorbrena (lorlatinib) (ALK inhibitor, ROS1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Metastatic Anaplastic Lymphoma Kinase-1 (ALK-1)-Rearranged Inflammatory Myofibroblastic Sarcoma to the Brain with Leptomeningeal Involvement: Favorable Response to Serial ALK Inhibitors: A Case Report
Excerpt:
We report a rare case of pulmonary IMS with ALK-1 gene rearrangement and multiple brain metastases as initial presentation...Unfortunately, her CNS disease progressed on follow-up brain MRI after being on crizotinib (250 mg bid) for three months. Crizotinib was discontinued, and she was started on ceritinib (Novartis, 750 mg qd)...and after eight months her CNS disease progressed again on brain MRI.
DOI:
10.12659/AJCR.903698
